---
title: "Imsidolimab in Generalized pustular psoriasis: Clinical evidence"
description: "Formulary evidence on Imsidolimab in Generalized pustular psoriasis: Clinical evidence. Covers GEMINI-1, GEMINI-2, GALLOP, Effisayil 1, Effisayil 2, and ANB019-001. 111 evidence topics quoted from 28 sources."
canonical: "https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imsidolimab in Generalized pustular psoriasis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 GEMINI-1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary objective: treatment of GPP flares

> “To evaluate the efficacy of imsidolimab compared with placebo”

Source: [ClinicalTrials.gov NCT05352893 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/Prot_000.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Geographic scope of the phase 3 program

> “26 clinical sites within 11 countries”

Source: [Smieszek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42047557/)

<a id="topic-3.1.1.2-2"></a>

###### Registry dates

| Milestone | Reported date |
| --- | --- |
| First participant enrollment | “14/04/2022” |
| Last data collection | “17/08/2023” |

Source: [ANZCTR NCT05352893](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20464&isClinicalTrial=True)

Additional sources: [ClinicalTrials.gov NCT05352893](https://clinicaltrials.gov/study/NCT05352893)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### GEMINI-1: design and allocation

> “a four week, double-blind, placebo-controlled, randomized study”
> “randomized 1:1:1”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

Additional sources: [Gudjonsson et al. (2022)](https://www.jaad.org/article/S0190-9622%2822%2901361-5/fulltext)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### GEMINI-1: flare eligibility criteria

> “BSA affected with pustules [excluding palms and soles] of at least 5%”
> “GPPPGA score of at least 3”
> “PRS score of at least 3”

Source: [ClinicalTrials.gov NCT05352893 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/Prot_000.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion of immediately life-threatening flares

> “Subject flare is so severe that patient's life is at risk”

Source: [ANZCTR NCT05352893](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20464&isClinicalTrial=True)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### GEMINI-1: randomized treatment

> “750mg IV imsidolimab, 300mg IV imsidolimab or placebo”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using GPPPGA Response as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### GPPGA and GPPASI validation

> “the GPPGA and GPPASI are valid, reliable and responsive measures for the assessment of GPP disease severity”

Source: [Burden et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18999)

<a id="topic-3.1.1.6.1-2"></a>

###### Prespecified primary and key secondary response thresholds

| Endpoint | Response threshold |
| --- | --- |
| Primary: GPPPGA at week 4 | “0 (clear) or 1 (almost clear)” |
| Key secondary: PRS at week 1 | “0 (clear) or 1 (almost clear)” |

Source: [ClinicalTrials.gov NCT05352893 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/Prot_000.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### GEMINI-1: enrolled participants and treatment groups

> “45 patients, 15 patients per arm”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned sample size and marginal power assumptions

| Parameter | Value |
| --- | --- |
| Total planned participants | “45” |
| Participants per group | “15” |
| Power for each marginal hypothesis test | “82%” |
| Assumed absolute difference in response proportions | “43.3%” |

Source: [ClinicalTrials.gov NCT05352893 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Prespecified analysis populations

| Analysis population | Definition excerpt |
| --- | --- |
| Intention-to-treat population | “all randomized subjects” |
| Safety population: exposure requirement for randomized participants | “receive 1 dose of imsidolimab or placebo” |

Source: [ClinicalTrials.gov NCT05352893 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf)

<a id="topic-3.1.1.7.2-2"></a>

###### Prespecified primary analysis and multiplicity sequence

| Method | Protocol wording |
| --- | --- |
| Primary response comparison, stratified by baseline GPPPGA | “Cochran-Mantel-Haenszel (CMH) Chi-square test” |
| Sequence: 750-mg primary, 750-mg key secondary, 300-mg primary, 300-mg key secondary | “H1→ H3→ H2→ H4” |
| Missing primary endpoint scores after dropout | “Multiple Imputations” |

Source: [ClinicalTrials.gov NCT05352893 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Placebo participants requiring early crossover to imsidolimab

> “66.7% (10/15)”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### GEMINI-1: week 4 results

| Endpoint                            | “300 mg”         | “750 mg”         | “placebo”        |
| ----------------------------------- | ---------------- | ---------------- | ---------------- |
| “GPPPGA scores of 0 or 1 at week 4” | “53%” “(n=8/15)” | “53%” “(n=8/15)” | “13%” “(n=2/15)” |
| P value                             | “P=0.023”        | “P=0.023”        |                  |

Source: [Smieszek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42047557/)

<a id="topic-3.1.1.8.3-2"></a>

###### Earlier sponsor report: 750-mg primary endpoint comparison

> “p=0.0131”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="topic-3.1.1.8.3-3"></a>

###### Key secondary endpoint: PRS 0 or 1 at week 1

| Randomized group | Response percentage |
| --- | --- |
| Imsidolimab 750 mg IV | “40.0” |
| Imsidolimab 300 mg IV | “66.7” |
| Placebo | “13.3” |

Source: [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf)

Additional sources: [Smieszek et al. (2025)](https://www.jidonline.org/article/S0022-202X%2825%2903089-1/fulltext)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Serious and severe adverse events in imsidolimab-treated participants

> “No SAEs or severe AEs reported in imsidolimab-treated patients”

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="topic-3.1.1.8.5-2"></a>

###### Anti-drug antibodies in imsidolimab-treated participants

| Measure | Reported finding |
| --- | --- |
| Participants with detectable antibodies | “One of 30 (3.3%)” |
| Neutralizing activity | “non-neutralizing” |

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The trial included 45 participants, with 15 per group, and a four-week placebo-controlled period. Ten of 15 placebo participants required early crossover. These features limit precision and longer-term randomized comparisons. The protocol excluded flares considered immediately life-threatening, limiting direct applicability to that population. The prespecified testing sequence placed the 750-mg key secondary endpoint before the 300-mg primary endpoint; individual reported P values should not be interpreted as independent of that sequence.

Source: [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/); [ANZCTR NCT05352893](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20464&isClinicalTrial=True); [ClinicalTrials.gov NCT05352893 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 GEMINI-2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Primary objective

> “long-term safety of imsidolimab”

Source: [ClinicalTrials.gov NCT05366855 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/Prot_000.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### GEMINI-2: follow-up reported with the initial extension results

> “Patients were followed for at least 24 weeks and up to a maximum of 92 weeks.”

Source: [AnaptysBio (2024)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-gemini-2-phase-3-clinical)

Additional sources: [ClinicalTrials.gov NCT05366855](https://clinicaltrials.gov/study/NCT05366855)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Treatment assignment according to response in GEMINI-1

> “Treatment in GEMINI-2 was based on their responder status in GEMINI-1”

Source: [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf)

<a id="topic-3.1.2.3-2"></a>

###### Safety follow-up described in the subsequent publication

> “evaluating the safety of imsidolimab up to 104 weeks”

Source: [Smieszek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42047557/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Prior participation requirement

> “have participated in the ANB019-301 study”

Source: [ClinicalTrials.gov NCT05366855 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/Prot_000.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Randomized maintenance treatment for initial responders

> “imsidolimab 200 mg or placebo every 4 weeks starting on Day 1.”

Source: [ClinicalTrials.gov NCT05366855 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/Prot_000.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

Not applicable.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### GEMINI-2: sample size and power

> “No formal sample size or power calculations were performed for this extension study.”

Source: [ClinicalTrials.gov NCT05366855 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/SAP_001.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### GEMINI-2: statistical hypothesis

> “There is no formal statistical hypothesis.”

Source: [ClinicalTrials.gov NCT05366855 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/SAP_001.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Prespecified analysis populations

| Analysis population | Definition excerpt |
| --- | --- |
| Intention-to-treat population | “all enrolled subjects” |
| Modified intention-to-treat population: previous response threshold | “GPPPGA score of 0 [clear] or 1 [almost clear]” |
| Extension safety population: treatment exposure requirement | “received at least one dose of imsidolimab or placebo” |

Source: [ClinicalTrials.gov NCT05366855 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Planned comparison of categorical efficacy outcomes

> “Farrington-Manning score test”

Source: [ClinicalTrials.gov NCT05366855 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/SAP_001.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Extension enrollment and treatment groups

| Population | Participants |
| --- | --- |
| Rolled over from GEMINI-1 | “42” |
| Initial responders randomized to imsidolimab maintenance | “8” |
| Initial responders randomized to placebo maintenance | “8” |
| Partial responders receiving imsidolimab maintenance | “12” |
| Placebo nonresponders receiving IV rescue followed by SC maintenance | “9” |
| Imsidolimab nonresponders receiving other available therapy | “5” |

Source: [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### GEMINI-2: maintenance and flare prevention

| Endpoint              | “Imsidolimab (n=8)” | “PBO (n=8)” |
| --------------------- | ------------------- | ----------- |
| “GPPPGA score of 0/1” | “100%”              | “25%”       |
| “flared (GPPPGA ≥3)”  | “0”                 | “62.5%”     |

Source: [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### GEMINI-2: serious adverse events and discontinuation

> “No SAEs led to study treatment discontinuation/withdrawal”

Source: [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### GEMINI-2: infusion reactions

> “No infusion reactions reported”

Source: [AnaptysBio (2024)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-gemini-2-phase-3-clinical)

<a id="topic-3.1.2.8.5-3"></a>

###### GEMINI-2: immunogenicity

> “low incidence of anti-drug antibodies”

Source: [Vanda Pharmaceuticals BLA acceptance announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/16791/pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The randomized maintenance comparison included 16 initial responders, eight per group, rather than all 42 extension participants. Its results therefore apply to a responder-enriched population. Other extension groups received nonrandomized treatment according to prior response. The statistical analysis plan specified no formal hypothesis and no formal sample size or power calculation. The small randomized groups limit precision for flare prevention and uncommon adverse events.

Source: [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf); [ClinicalTrials.gov NCT05366855 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/SAP_001.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 GALLOP

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Imsidolimab in participants with GPP

> “efficacy and safety”

Source: [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Geographic scope reported by the sponsor

> “United States and Europe”

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

Additional sources: [ClinicalTrials.gov NCT03619902](https://clinicaltrials.gov/study/NCT03619902)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase 2 study design

> “open-label, single-arm, multiple-dose study”

Source: [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Disease activity thresholds described in the sponsor report

| Inclusion criterion | Minimum value |
| --- | --- |
| Modified Japanese Dermatology Association severity index | “7” |
| Body surface area with active pustules and erythema | “10%” |

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### GALLOP: dosing

> “750mg IV dose of imsidolimab”
> “monthly 100mg subcutaneous dose of imsidolimab beginning at Week 4 and continued through Week 12.”

Source: [AnaptysBio British Journal of Dermatology publication announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-announces-british-journal-dermatology-publication)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using CGI Response as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint and assessment times

> “clinical response at weeks 4 and 16”

Source: [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/)

<a id="topic-3.1.3.6.1-2"></a>

###### Independent validation of the primary response definition

No evidence found.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment

| Population | Approximate planned participants |
| --- | --- |
| GALLOP | “10” |

Source: [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Prespecified analysis populations

| Analysis population | Definition excerpt |
| --- | --- |
| Full analysis population | “all subjects” |
| Safety population: exposure requirement | “at least 1 dose” |

Source: [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Sponsor-reported imputation for missing severity-index data

> “last-observation-carry forward (LOCF)”

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Enrollment and completion

> “Eight patients were enrolled and six completed the study.”

Source: [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline disease burden in the sponsor results table

| Measure | Reported baseline |
| --- | --- |
| Modified Japanese Dermatology Association severity index | “9” |
| Body surface area with erythema and pustules | “24%” |
| DLQI | “16” |

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### CGI response at both week 4 and week 16

> “Six of 8 (75%)”

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="topic-3.1.3.8.3-2"></a>

###### GPPPGA response in the subgroup assessed after protocol amendment

| Measure | Reported value |
| --- | --- |
| Participants assessed | “4” |
| GPPPGA 0 or 1 at week 4 | “2 (50%)” |
| GPPPGA 0 or 1 at week 16 | “3 (75%)” |

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### DLQI change relative to baseline in the sponsor results table

| Assessment | Change in score |
| --- | --- |
| Week 4 | “-6” |
| Week 16 | “-11” |

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### GALLOP: safety

> “Two patients experienced serious adverse events (SAEs); no deaths were reported.”

Source: [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/)

<a id="topic-3.1.3.8.5-2"></a>

###### Serious Staphylococcal aureus bacteremia: investigator causality assessment

> “possibly drug-related”

Source: [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

GALLOP was open-label and single-arm, with eight participants enrolled and six completing the study. Without a randomized control group, observed improvement cannot establish the treatment effect separately from the natural course of a flare. GPPPGA results were reported for four participants after a protocol amendment, whereas CGI response used the full cohort. This limits comparison of the response percentages across instruments.

Source: [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/); [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)

<a id="heading-3.1.4"></a>

#### 3.1.4 Effisayil 1

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Spesolimab versus placebo during an acute GPP flare

> “efficacy, safety and tolerability”

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Trial dates and geographic scope

| Characteristic | Reported value |
| --- | --- |
| Start date | “February 20, 2019” |
| End date | “January 5, 2021” |
| Countries with enrolling sites | “12” |

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized comparator trial

> “randomised, double-blind, placebo-controlled”

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Permitted age range

> “18 to 75 years”

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="topic-3.1.4.4-2"></a>

###### Acute-flare eligibility thresholds

| Criterion | Threshold |
| --- | --- |
| GPPGA total score | “≥3” |
| GPPGA pustulation subscore | “≥2” |
| Body surface area with erythema and pustules | “≥5%” |

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Single intravenous spesolimab dose compared with placebo

| Treatment | Dose in mg |
| --- | --- |
| Spesolimab | “900” |

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using GPPGA Pustulation Subscore as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Meaning of a pustulation subscore of zero at week 1

> “complete pustular clearance”

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="topic-3.1.4.6.1-2"></a>

###### GPPGA and GPPASI validation

> “the GPPGA and GPPASI are valid, reliable and responsive measures for the assessment of GPP disease severity”

Source: [Burden et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18999)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment and power

| Parameter | Value |
| --- | --- |
| Planned participants | “51” |
| Overall power for the primary and key secondary endpoints simultaneously | “93.9%” |

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Randomized participants

| Population | Participants |
| --- | --- |
| Total enrolled | “53” |
| Spesolimab | “35” |
| Placebo | “18” |

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Population for the primary and key secondary endpoints

> “intention-to-treat population”

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Prespecified endpoint testing

| Method | Quoted description |
| --- | --- |
| Comparison of response proportions | “Suissa-Shuster Z-pooled test” |
| Multiplicity control | “hierarchical manner” |

Source: [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Open-label spesolimab at week 1

| Randomized group and measure | Reported value |
| --- | --- |
| Spesolimab: participants and percentage receiving another dose | “12 (34%)” |
| Placebo: participants receiving spesolimab | “15” |
| Placebo: percentage receiving spesolimab | “(83%)” |

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Overall trial population

| Characteristic | Reported value |
| --- | --- |
| Mean age in years | “43” |
| Female participants | “68%” |

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Week 1 response: participants and percentages

| Endpoint | Spesolimab | Placebo |
| --- | --- | --- |
| Primary: GPPGA pustulation subscore 0 | “19 (54)” | “1 (6)” |
| Key secondary: GPPGA total score 0 or 1 | “15 (43)” | “2 (11)” |

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="topic-3.1.4.8.3-2"></a>

###### Week 1 response comparisons

| Endpoint | P value |
| --- | --- |
| Primary | “<0.001” |
| Key secondary | “0.02” |

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Week 4 symptom and fatigue endpoints after open-label treatment: analysis approach

> “reported descriptively”

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Comparator trial: spesolimab, Effisayil 1

> “Among patients assigned to the spesolimab group, infections occurred in 6 of 35 (17%) through the first week”

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The trial enrolled 53 participants. The primary randomized comparison was assessed at week 1; subsequently, 12 participants initially assigned to spesolimab and 15 initially assigned to placebo received open-label spesolimab. This limits interpretation of later outcomes as randomized treatment comparisons. The publication consequently reported later symptom and fatigue outcomes descriptively. This was a placebo-controlled spesolimab study, not a comparison with imsidolimab.

Source: [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf); [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="heading-3.1.5"></a>

#### 3.1.5 Effisayil 2

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Maintenance treatment and flare prevention

> “prevents the occurrence of GPP flares”

Source: [Morita et al. (2022)](https://link.springer.com/article/10.1007/s13555-022-00835-6)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Geographic scope

> “This multicentre, randomised, placebo-controlled, phase 2b trial was done at 60 hospitals and clinics in 20 countries.”

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="topic-3.1.5.2-2"></a>

###### Trial dates

| Milestone | Reported date |
| --- | --- |
| Start | “June 8, 2020” |
| End | “Nov 23, 2022” |

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized dose-finding study

> “phase 2, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding study”

Source: [Morita et al. (2022)](https://link.springer.com/article/10.1007/s13555-022-00835-6)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Required flare history

> “at least two GPP flares”

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="topic-3.1.5.4-2"></a>

###### GPPPGA total score at screening and randomization

> “0 or 1”

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Investigated subcutaneous spesolimab regimens

| Regimen | Loading dose in mg | Maintenance dose in mg | Maintenance interval in weeks |
| --- | --- | --- | --- |
| High dose | “600” | “300” | “4” |
| Medium dose | “600” | “300” | “12” |
| Low dose | “300” | “150” | “12” |

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Time to First GPP Flare as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Flare definition for the primary endpoint through week 48

| Required component | Threshold |
| --- | --- |
| GPPPGA pustulation subscore | “≥2” |
| Increase in GPPPGA total score from baseline | “≥2” |

Source: [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="topic-3.1.5.6.1-2"></a>

###### GPPGA and GPPASI validation

> “the GPPGA and GPPASI are valid, reliable and responsive measures for the assessment of GPP disease severity”

Source: [Burden et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18999)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned enrollment

| Population | Participants |
| --- | --- |
| Total planned | “120” |

Source: [Morita et al. (2022)](https://link.springer.com/article/10.1007/s13555-022-00835-6)

<a id="topic-3.1.5.7.1-2"></a>

###### Screening and randomization

| Population | Participants |
| --- | --- |
| Screened | “157” |
| Randomized | “123” |

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Prespecified time-to-event analyses

| Analysis | Method |
| --- | --- |
| Hazard ratios for dose-response testing, stratified by systemic GPP medication use at randomization | “stratified Cox regression model” |
| Individual-dose comparison with placebo, with the same stratification | “stratified log-rank test” |

Source: [Morita et al. (2022)](https://link.springer.com/article/10.1007/s13555-022-00835-6)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Randomized treatment groups

| Group | Participants |
| --- | --- |
| High-dose spesolimab | “30” |
| Medium-dose spesolimab | “31” |
| Low-dose spesolimab | “31” |
| Placebo | “31” |

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Sex distribution

| Characteristic | Participants and percentage |
| --- | --- |
| Female | “76 [62%]” |

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Participants with a GPP flare by week 48

| Group | Participants and percentage |
| --- | --- |
| High-dose spesolimab | “three (10%)” |
| Placebo | “16 (52%)” |

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="topic-3.1.5.8.3-2"></a>

###### High-dose spesolimab versus placebo: time to first flare

| Measure | Reported value |
| --- | --- |
| Hazard ratio | “0·16” |
| 95% confidence interval | “0·05-0·54” |
| P value | “0·0005” |

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### Definition of the symptom and quality-of-life endpoints

> “Other secondary endpoints included time to worsening (defined as an increase of four points from baseline for each score) of the Psoriasis Symptom Scale (PSS) and Dermatology Life Quality Index (DLQI) up to week 48, and the occurrence of adverse events by week 48.”

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="topic-3.1.5.8.4-2"></a>

###### Time to worsening of the Psoriasis Symptom Scale

> “Spesolimab reduced the risk of PSS worsening over 48 weeks compared with placebo, as demonstrated by HRs of 0·46 (95% CI 0·22–0·95, nominal p=0·0079) for the low-dose regimen, 0·56 (95% CI 0·28–1·10, nominal p=0·052) for the medium-dose regimen, and 0·42 (0·20–0·91, p=0·013) for the high-dose regimen”
> “A smaller proportion of patients in the low-dose (12 [39%] of 31), medium-dose (14 [45%] of 31), and high-dose (ten [33%] of 30) spesolimab groups reported a worsening of their PSS score compared with placebo (20 [65%] of 31; figure 3A and appendix p 11).”
> “High-dose spesolimab did not pass the significance threshold for superiority (α=0·0063) for time to worsening of PSS (p=0·013) and no further testing was done.”

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="topic-3.1.5.8.4-3"></a>

###### Time to worsening of the Dermatology Life Quality Index

> “Spesolimab reduced the risk of DLQI worsening over 48 weeks, with HRs versus placebo of 0·58 (95% CI 0·30–1·14, nominal p=0·043) for the low-dose group, 0·60 (0·31–1·17, nominal p=0·048) for the medium-dose group, and 0·26 (0·11–0·62, nominal p=0·0010) for the high-dose group”

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

Additional sources: [Morita et al. (2022)](https://link.springer.com/article/10.1007/s13555-022-00835-6)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Mortality during the trial

> “no deaths”

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The trial enrolled participants with a history of at least two GPP flares who had clear or almost clear skin at screening and randomization. It therefore addresses flare prevention rather than initial treatment of an active flare. The high-dose group included 30 participants and the placebo group 31, limiting precision for uncommon harms. Follow-up for the primary endpoint extended to 48 weeks. The comparator was placebo, not imsidolimab.

Source: [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/); [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)

<a id="heading-3.1.6"></a>

#### 3.1.6 ANB019-001

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Primary objective in the first-in-human study

> “safety and tolerability”

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study site

> “Nucleus Network - Melbourne”

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="topic-3.1.6.2-2"></a>

###### Registry dates

| Milestone | Reported date |
| --- | --- |
| First participant enrollment | “3/04/2017” |
| Last participant enrollment | “26/09/2017” |
| Last data collection | “15/01/2018” |

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Healthy-volunteer trial design

> “double-blind, placebo-controlled healthy volunteer Phase 1 trial”

Source: [AnaptysBio (2017)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-anb019-top-line-phase-1-clinical)

<a id="topic-3.1.6.3-2"></a>

###### Randomization ratio in the healthy-volunteer cohorts

> “randomized (3:1)”

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="topic-3.1.6.3-3"></a>

###### Allocation concealment

> “Sealed opaque envelopes”

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Registered age range

| Criterion | Value |
| --- | --- |
| Minimum age | “18 Years” |
| Maximum age | “65 Years” |

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Single ascending doses: studied range

> “10 mg and 750 mg”

Source: [AnaptysBio (2017)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-anb019-top-line-phase-1-clinical)

<a id="topic-3.1.6.5-2"></a>

###### Multiple ascending intravenous doses: studied range and frequency

> “40 mg and 300 mg weekly for four consecutive weeks”

Source: [AnaptysBio (2017)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-anb019-top-line-phase-1-clinical)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Registered enrollment

| Population | Participants |
| --- | --- |
| Target enrollment | “87” |
| Final enrollment | “73” |

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="topic-3.1.6.7.1-2"></a>

###### Healthy volunteers in the congress poster

| Population | Participants |
| --- | --- |
| Total reported | “72” |
| Single ascending dose cohorts | “48” |
| Multiple ascending dose cohorts | “24” |

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Safety populations in the congress poster

| Population | Participants |
| --- | --- |
| Single ascending dose: ANB019 | “36” |
| Single ascending dose: placebo | “12” |
| Multiple ascending dose: ANB019 | “18” |
| Multiple ascending dose: placebo | “6” |

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="topic-3.1.6.7.2-2"></a>

###### Safety assessment method specified in the registry

> “medical review of adverse event reports”

Source: [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Poster-reported assessment period

> “85 days”

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Healthy-volunteer pharmacokinetics: half-life and subcutaneous bioavailability

> “Median terminal half life ranged between 597 and 689 hours (25 to 29 days).”
> “Bioavailability was approximately 90%”

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="topic-3.1.6.8.3-2"></a>

###### Clinical efficacy in GPP

Not applicable.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Treatment-emergent adverse events: participants and percentages

| Cohort | ANB019 | Placebo |
| --- | --- | --- |
| Single ascending dose | “29 (81%)” | “11 (92%)” |
| Multiple ascending dose | “16 (89%)” | “3 (50%)” |

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="topic-3.1.6.8.5-2"></a>

###### Serious adverse events across all participants in each dose-escalation part

| Population | Participants and percentage |
| --- | --- |
| Single ascending dose | “0 (0%)” |
| Multiple ascending dose | “0 (0%)” |

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

The congress poster reports 72 healthy volunteers, including 48 in the single ascending dose cohorts and 24 in the multiple ascending dose cohorts, with an assessment period of 85 days. These data do not establish clinical efficacy in GPP or longer-term safety during chronic treatment. The registry lists 73 participants overall, whereas the poster reports 72 healthy volunteers; the available evidence in this report does not reconcile that difference.

Source: [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf); [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)

## Related pages
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis.md)
- [Imsidolimab in Generalized pustular psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations.md)
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/executive-summary.md)
- [Imsidolimab in Generalized pustular psoriasis: Product information and disease description](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/product-information-and-disease-description.md)
- [Imsidolimab in Generalized pustular psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economics.md)
- [Imsidolimab in Generalized pustular psoriasis: References](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/references.md)
- [Imsidolimab in Generalized pustular psoriasis: prevalence by geography](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/prevalence) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/prevalence.md)
- [Imsidolimab in Generalized pustular psoriasis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/cost-effectiveness-analyses.md)
